NPI: 1578992558 · HOMESTEAD, FL 33033 · End-Stage Renal Disease (ESRD) Treatment Clinic/Center · NPI assigned 11/11/2013
Authorized official WEY, SAMUEL controls 20+ related entities in our dataset. Read more
| Authorized Official | WEY, SAMUEL (VP, LICENSURE & CERTIFICATION) |
| NPI Enumeration Date | 11/11/2013 |
Other providers sharing the same authorized official: WEY, SAMUEL
| Provider | City | State | Total Paid |
|---|---|---|---|
| DVA HEALTHCARE RENAL CARE INC | NORTH HOLLYWOOD | CA | $16.47M |
| DVA HEALTHCARE RENAL CARE INC | DELANO | CA | $16.43M |
| DVA RENAL HEALTHCARE INC | LOS ANGELES | CA | $15.51M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $14.93M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.67M |
| DVA RENAL HEALTHCARE INC | OAKLAND | CA | $13.42M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $13.25M |
| DVA HEALTHCARE RENAL CARE INC | YUMA | AZ | $12.88M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $12.77M |
| DVA RENAL HEALTHCARE INC | FULLERTON | CA | $12.19M |
| DVA HEALTHCARE RENAL CARE INC | POMONA | CA | $11.96M |
| DVA RENAL HEALTHCARE INC | ANAHEIM | CA | $11.32M |
| DVA RENAL HEALTHCARE INC | ESCONDIDO | CA | $10.94M |
| DVA HEALTHCARE RENAL CARE INC | COSTA MESA | CA | $10.08M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $9.46M |
| DVA RENAL HEALTHCARE INC | VISALIA | CA | $9.22M |
| DVA RENAL HEALTHCARE INC | SAN DIEGO | CA | $8.83M |
| DVA HEALTHCARE RENAL CARE INC | BAKERSFIELD | CA | $8.56M |
| DVA HEALTHCARE RENAL CARE INC | INGLEWOOD | CA | $7.78M |
| DVA RENAL HEALTHCARE INC | PALM SPRINGS | CA | $7.48M |
| Year | Claims | Total Paid |
|---|---|---|
| 2018 | 1,135 | $328K |
| 2019 | 8,799 | $1.52M |
| 2020 | 6,598 | $1.28M |
| 2021 | 4,709 | $581K |
| 2022 | 2,808 | $328K |
| Code | Description | Claims | Beneficiaries | Total Paid |
|---|---|---|---|---|
| 90999 | Unlisted dialysis procedure, inpatient or outpatient | 11,365 | 788 | $1.80M |
| Q4081 | Injection, epoetin alfa, 100 units (for esrd on dialysis) | 7,182 | 327 | $1.11M |
| J1270 | Injection, doxercalciferol, 1 mcg | 1,315 | 106 | $317K |
| A4657 | Syringe, with or without needle, each | 1,136 | 403 | $216K |
| 85041 | 534 | 228 | $104K | |
| 85048 | 525 | 227 | $103K | |
| 83550 | 493 | 230 | $99K | |
| 83540 | 493 | 230 | $99K | |
| 82728 | 433 | 203 | $92K | |
| J1756 | Injection, iron sucrose, 1 mg | 346 | 40 | $54K |
| 83970 | 187 | 120 | $35K | |
| G0499 | Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result | 40 | 12 | $12K |